FDA Grants Investigational New Drug Status for BioMarin’s BMN 270 Hemophilia A Therapy
The U.S. Food and Drug Administration (FDA) has approved BioMarin Pharmaceutical‘s Investigational New Drug (IND) application for its gene therapy candidate BMN 270 to treat severe hemophilia A. FDA’s decision on BMN 270, also known for…